Neovacs S.A Anno IPO
Cos'è Anno IPO di Neovacs S.A?
Anno IPO di Neovacs S.A. è 2010
Qual è la definizione di Anno IPO?
L'offerta pubblica iniziale è un tipo di offerta pubblica in cui le azioni di una società di solito sono vendute a investitori istituzionali che, a loro volta, vendono al pubblico in generale, su una borsa valori, per la prima volta.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Anno IPO di aziende nel Health Care settore su EURONEXT rispetto a Neovacs S.A
Cosa fa Neovacs S.A?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Aziende con anno ipo simili a Neovacs S.A
- Chigo ha Anno IPO di 2009
- Jade Road Investments ha Anno IPO di 2009
- Equity Metals ha Anno IPO di 2009
- Kerr Mines ha Anno IPO di 2009
- China e-Wallet Payment ha Anno IPO di 2009
- SQS India BFSI ha Anno IPO di 2009
- Neovacs S.A ha Anno IPO di 2010
- Broken Hill Prospecting ha Anno IPO di 2011
- Apollo Global Management Inc ha Anno IPO di 2011
- Hipo Resources ha Anno IPO di 2011
- Cogra 48 SA ha Anno IPO di 2011
- New Mountain Finance Corp ha Anno IPO di 2011
- Marfrig Global Foods SA ha Anno IPO di 2011